The biopharmaceutical firm’s quarterly earnings reached 56 cents per share, significantly outperforming the 37 cents projected by analysts polled by FactSet. This performance marks a sharp rise from the $18.4 million profit reported during the same period last year. Total revenue reached $286 million, comfortably clearing the $260.7 million consensus estimate among Wall Street analysts.

Chief Executive Sanj Patel attributed the growth to effective commercial execution, noting increased adoption among both physicians and patients. The company now anticipates Arcalyst will achieve blockbuster status by the end of the year. Reflecting this confidence, Kiniksa raised its full-year net sales guidance for the drug to a range between $1.045 billion and $1.05 billion, a notable increase from the previous forecast of up to $995 million. Year-to-date, the company’s stock has climbed nearly 77%.